piwik-script

    Chair of Biochemistry and Molecular Biology

    AG Wolf

    Contact

    Prof. Dr. Elmar Wolf
    Lehrstuhl für Biochemie und Molekularbiologie
    Biozentrum
    Am Hubland
    97074 Würzburg
    Raum B 353

    Tel:   0931 31-83259
    Fax:  0931 31-84113
    elmar.wolf@biozentrum.uni-wuerzburg.de

    Emmy Noether group - Cancer Systems Biology

    Lab News

    March 2021
    Excited to be part of a research project about drugging MYC funded by the Alex´s Lemonade Stand Foundation for Childhood Cancer
    https://www.alexslemonade.org/project/drugging-mycn

    December 2020
    Great digital lab retreat together with the Dölken lab - thanks to Lars and his team! here

    September 2020
    Our paper on PROTACs for Aurora-A is online at Nature Chemical Biology. Well done, Bikash! See our paper and press release

    Archive

    Research



    In ageing Western societies tumors are becoming the most relevant medical problem. A key characteristic of tumors is deregulated signaling pathways that significantly alter the transcriptional profile of tumor cells. Proteins of the MYC family play a prominent role in this oncogenic reprogramming as transcription factors.

    Our vision is to understand the transcriptional changes during carcinogenesis and, in particular, the oncogenic function of Myc to the extent that new pharmaceutical strategies for the fight against cancer can be developed on this basis. To this end, my research group uses genome- and proteome-wide methods to better understand the biology of tumors as well as genetic screens to find potential therapeutic targets of tumor cells. Together with our partners, we have recently developed substances that inhibit the function of Myc. In the next few years, we want to improve these molecules, of the PROTAC substance class, to such an extent that they can be clinically tested and applied.


    Research topic 1: The oncogenic function of MYC

    Research topic 2: Investigation of transcriptional elongation

    Research topic 3: New pharmaceutical concepts in oncology

    Publications

    Recent:

    Adhikari B, Bozilovic J, Diebold M,Schwarz JD, Hofstetter J, Schröder M, Wanior M, Narain A, Vogt M, DudvarskiStankovic N, Baluapuri A, Schönemann L, Eing L, Bhandare P, Kuster B, SchlosserA, Heinzlmeir S, Sotriffer C, Knapp S* WolfE*, PROTAC-mediated degradation reveals a non-catalytic function ofAURORA-A kinase, Nature Chemical Biology, 2020,

    Wolpaw AJ, Bayliss R, Büchel G, Dang CV, Eilers M, Gustafson WC, Hansen GM, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mossé YP (2021) Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers, Cancer Research,  doi: 10.1158/0008-5472.CAN-20-3108

    Endres T, Solvie D, Heidelberger J ,Andrioletti V ,Baluapuri A ,Ade CP, Muhar M, Eilers U, Vos SM, Cramer P, Zuber J, Beli P, Popov N, Wolf E, Gallant P, Eilers M: Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters, Molecular Cell, in press

    Jessen C, Kreß JKC, Baluapuri A, Hufnagel A, Schmitz W,Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP, Glutsch V, Wobser M,Friedmann-Angeli JP, Mosteo L, Goding CR, Schilling B, Geissinger E, Wolf E, Meierjohann S, The transcriptionfactor NRF2 enhances melanoma malignancy by blocking differentiation andinducing COX2 expression, Oncogene, 2020, doi:10.1038/s41388-020-01477-8

    Wolf E and Eilers M: Targeting MYC Proteins for Tumor Therapy, Annual Review of Cancer Biology, 2020, 4

    Show all

    Link to all Publications in PubMed